Several analysts have recently updated their ratings and price targets for Endologix (NASDAQ: ELGX):

  • 8/4/2017 – Endologix was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 8/4/2017 – Endologix had its “hold” rating reaffirmed by analysts at Canaccord Genuity. They wrote, “Alimera reported 2Q17 Iluvien US sales of $8.1M which was above our estimate of.””
  • 8/3/2017 – Endologix was given a new $5.00 price target on by analysts at Oppenheimer Holdings, Inc.. They now have a “hold” rating on the stock.
  • 8/2/2017 – Endologix was given a new $6.00 price target on by analysts at Stifel Nicolaus. They now have a “hold” rating on the stock.
  • 7/31/2017 – Endologix had its “hold” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $5.00 price target on the stock.
  • 7/25/2017 – Endologix was downgraded by analysts at Zacks Investment Research from a “strong-buy” rating to a “hold” rating. According to Zacks, “Endologix, Inc. develops, manufactures and markets products for the treatment of coronary and vascular diseases. A leader in the emerging field of vascular brachytherapy, Endologix, has developed a unique method for the delivery of radiation to prevent restenosis following the interventional treatment of atherosclerosis. “
  • 7/24/2017 – Endologix was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “strong-buy” rating. They now have a $5.75 price target on the stock. According to Zacks, “Endologix, Inc. develops, manufactures and markets products for the treatment of coronary and vascular diseases. A leader in the emerging field of vascular brachytherapy, Endologix, has developed a unique method for the delivery of radiation to prevent restenosis following the interventional treatment of atherosclerosis. “

Endologix, Inc. (NASDAQ:ELGX) traded up 0.36% during mid-day trading on Monday, hitting $4.19. 129,680 shares of the stock traded hands. Endologix, Inc. has a 1-year low of $4.08 and a 1-year high of $13.30. The stock has a 50-day moving average of $4.91 and a 200 day moving average of $6.07. The firm’s market cap is $349.55 million.

Endologix (NASDAQ:ELGX) last released its quarterly earnings results on Wednesday, August 2nd. The medical instruments supplier reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.08. The business had revenue of $48.60 million during the quarter, compared to analyst estimates of $47.58 million. Endologix had a negative net margin of 40.77% and a negative return on equity of 44.60%. The company’s quarterly revenue was down 4.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.20) earnings per share. On average, equities analysts expect that Endologix, Inc. will post ($0.60) EPS for the current year.

In related news, Director Guido J. Neels bought 20,000 shares of the firm’s stock in a transaction that occurred on Friday, May 19th. The stock was purchased at an average price of $4.32 per share, for a total transaction of $86,400.00. Following the transaction, the director now directly owns 61,380 shares of the company’s stock, valued at approximately $265,161.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Dan Lemaitre bought 22,522 shares of the firm’s stock in a transaction that occurred on Monday, May 22nd. The stock was bought at an average price of $4.43 per share, with a total value of $99,772.46. Following the transaction, the director now directly owns 68,689 shares in the company, valued at $304,292.27. The disclosure for this purchase can be found here. Insiders have bought 44,722 shares of company stock valued at $195,676 in the last 90 days. Insiders own 4.10% of the company’s stock.

Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.

Receive News & Ratings for Endologix Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix Inc and related companies with MarketBeat.com's FREE daily email newsletter.